Gogishvili T, Danhof S, Prommersberger S, Rydzek J, Schreder M, Brede C, Einsele H, Hudecek M

(2017) SLAMF7-CAR T cells eliminate myeloma and confer selective fratricide of SLAMF7+

normal lymphocytes. Blood 130(26):2838–2847. https://doi.org/10.1182/blood-2017-

04-778423

Jensen MC, Riddell SR (2015) Designing chimeric antigen receptors to effectively and safely target

tumors. Curr Opin Immunol 33:9–15. https://doi.org/10.1016/j.coi.2015.01.002

Johnsen HE, Bøgsted M, Schmitz A, Bødker JS, El-Galaly TC, Johansen P, Valent P, Zojer N, Van

Valckenborgh E, Vanderkerken K, Van Duin M, Sonneveld P, Perez-Andres M, Orfao A,

Dybkær K (2016) The myeloma stem cell concept, revisited: from phenomenology to opera-

tional terms. Haematologica 101(12):1451–1459. https://doi.org/10.3324/haematol.2015.

138826

Lingzhi Y, Jingjing S, Liqing K, Xiaolan S, Jin Z, Song J, Weiqin Y, Ying Y, Guanghua C,

Ziling Z, Huirong C, Depei W, Lei Y, Chengcheng F (2017) Combined infusion of CD19 and

BCMA-specific chimeric antigen receptor T cells for RRMM: initial safety and efficacy report

from a clinical pilot study. Blood 130(1):506. https://doi.org/10.1182/blood.V130.Suppl_1.

506.506

Rajkumar SV, Dimopoulos MA, Palumbo A, Blade J, Merlini G, Mateos MV, Kumar S,

Hillengass J, Kastritis E, Richardson P, Landgren O, Paiva B, Dispenzieri A, Weiss B,

LeLeu X, Zweegman S, Lonial S, Rosinol L, Zamagni E, Miguel JFS (2014) International

Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol

15(12):e538–e548. https://doi.org/10.1016/S1470-2045(14)70442-5

Ramos CA, Savoldo B, Torrano V, Ballard B, Zhang H, Dakhova O, Liu E, Carrum G, Kamble RT,

Gee AP, Mei Z, Wu MF, Liu H, Grilley B, Rooney CM, Brenner MK, Heslop HE, Dotti G

(2016) Clinical responses with T lymphocytes targeting malignancy-associated κ light chains. J

Clin Invest 126(7):2588–2596. https://doi.org/10.1172/JCI86000

Sanchez E, Gillespie A, Tang G, Ferros M, Harutyunyan NM, Vardanyan S, Gottlieb J, Li M, Wang

CS, Chen H, Berenson JR (2016) Soluble B-cell maturation antigen mediates tumor-induced

immune deficiency in multiple myeloma. Clin Cancer Res 22(13):3383–3397. https://doi.org/

10.1158/1078-0432.CCR-15-2224

Sun C, Mahendravada A, Ballard B, Kale B, Ramos C, West J, Maguire T, McKay K, Lichtman E,

Tuchman S, Dotti G, Savoldo B (2019) Safety and efficacy of targeting CD138 with a chimeric

antigen receptor for the treatment of multiple myeloma. Oncotarget 10(24):2369–2383. https://

doi.org/10.18632/oncotarget.26792

Tai YT, Anderson KC (2015) Targeting B-cell maturation antigen in multiple myeloma. Immuno-

therapy 7(11):1187–1199. https://doi.org/10.2217/imt.15.77

Van Der Stegen SJC, Hamieh M, Sadelain M (2015) The pharmacology of second-generation

chimeric antigen receptors. Nat Rev Drug Discov 14(7):499–509. https://doi.org/10.1038/

nrd4597

Vincent Rajkumar S (2014) Multiple myeloma: 2014 update on diagnosis, risk-stratification, and

management. Am J Hematol 89(10):999–1009. https://doi.org/10.1002/ajh.23810

Walker RE, Lawson MA, Buckle CH, Snowden JA, Chantry AD (2014) Myeloma bone disease:

pathogenesis, current treatments and future targets. Br Med Bull 111(1):117–138. https://doi.

org/10.1093/bmb/ldu016

Xu S, Lam KP (2001) B-cell maturation protein, which binds the tumor necrosis factor family

members BAFF and APRIL, is dispensable for humoral immune responses. Mol Cell Biol

21(12):4067–4074. https://doi.org/10.1128/mcb.21.12.4067-4074.2001

25

Chimeric Antigen Receptor T Cell Therapy: A Cutting-Edge Therapy for. . .

481